Richard Borgens, Ph.D., and Purdue Researchers Report Progress on Program Licensed to Cyberkinetics Neurotechnology Systems, Inc.; Compound May Prevent Neural Cell Death

Business Wire, April 17, 2006

FOXBOROUGH, Mass. -- Cyberkinetics Neurotechnology Systems, Inc. (OTCBB:CYKN: "Cyberkinetics") announced that the Journal of Neuroscience published two studies conducted by research teams at Purdue University's Center for Paralysis Research concerning technology licensed to Cyberkinetics. Together, the studies indicate that hydralazine, already approved for other uses by the FDA, and certain related compounds may prevent neural cell death by halting the toxic chemical process that normally occurs following an injury. Cyberkinetics Neurotechnology Systems, Inc. holds an exclusive, worldwide license to this technology.

The Center for Paralysis Research at Purdue University is a world-renowned research group in the field of spinal cord injury. Dr. Borgens is the inventor of Cyberkinetics' Andara(TM) OFS (Oscillating Field Stimulator) Device technology, which is currently under FDA review to be designated as a Humanitarian Device for the regeneration of neural tissue damaged in spinal cord injury. The teams conducting the studies were led by Richard Borgens, Ph.D., founder of Purdue's Center for Paralysis Research, and the Mari Hulman George Professor of Applied Neurology in the School of Veterinary Medicine at Purdue, and Riyi Shi, M.D., Ph.D., Associate Professor, Department of Basic Medical Sciences and Biomedical Engineering at Purdue University. Drs. Borgens and Shi are scientific advisors of Cyberkinetics.

"The research reported today by my colleagues, Drs. Riyi Shi and Peishan Liu-Snyder, describes a fundamental discovery about the ability of a specific compound to prevent the loss of nerve cells following an injury, including a spinal cord injury," commented Dr. Borgens. "This discovery may enable us to tackle the root problem of the paralysis process."

"While the results from these studies are very early stage, today's publications underscore the long-term value of our relationship with Dr. Borgens and his team and the depth of the Purdue programs" added Timothy Surgenor, President and Chief Executive Officer of Cyberkinetics. "Though substantially more work will be required to translate this finding into clinical practice, we believe that hydralazine and related compounds represent a future opportunity for Cyberkinetics to be a leader in the ongoing convergence between drug and device therapies. In addition to the Purdue license, we have already secured an exclusive option to related intellectual property from the University of Adelaide in Australia in order to expand our ability to develop or partner its similar program."

About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, Inc., a leader in the neurotechnology industry, is developing neural stimulation, sensing and processing technology to improve the lives of those with severe paralysis resulting from spinal cord injuries, neurological disorders and other conditions of the nervous system. Cyberkinetics' product development pipeline includes: the FDA-approved NeuroPort(TM) System, a neural monitor designed for acute inpatient applications and labeled for temporary (less than 30 days) recording and monitoring of brain electrical activity; the Andara(TM) Oscillating Field Stimulator (OFS) Device, designed to stimulate regeneration of the neural tissue surrounding the spinal cord; and the BrainGate(TM) System, designed to provide communication and control of a computer, assistive devices and, ultimately, limb movement.

Copies of the abstracts related to the studies published in the Journal of Neuroscience, as well as additional information about Cyberkinetics and its programs are available at Cyberkinetics' website in the "Media Room" at http://www.cyberkineticsinc.com.

Forward-Looking Statement

This announcement contains forward-looking statements, including statements about Cyberkinetics' product development plans and progress, potential development of proprietary inventions and benefits that may be realized by certain research programs. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and can be identified by the use of forward-looking terminology such as "may," "will," "believe," "expect," "anticipate" or other comparable terminology. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected in forward-looking statements and reported results shall not be considered an indication of our future performance. Factors that might cause or contribute to such differences include our limited operating history; our lack of profits from operations; our ability to successfully develop and commercialize our proposed products; a lengthy approval process and the uncertainty of FDA and other governmental regulatory requirements; clinical trials may fail to demonstrate the safety and effectiveness of our products; the degree and nature of our competition; our ability to employ and retain qualified employees; compliance with recent legislation regarding corporate governance, including the Sarbanes-Oxley Act of 2002; as well as those risks more fully discussed in our public filings with the Securities and Exchange Commission, all of which are difficult to predict and some of which are beyond our control.